
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is well-positioned for sustained growth with a robust pipeline of approved drugs and promising candidates, particularly Uplizna in the rare disease segment. The company's financials are strong with increasing revenues and a dedicated focus towards innovation, signifying its long-term strength. Although there may be some near-term challenges due to patent expiration for certain drugs, the company's ongoing efforts in business development can lead to potential growth opportunities in the future.
Bears say
Amgen is facing declining revenue and potential market share loss due to challenges in their key drugs such as Enbrel and Wezlana, as well as upcoming biosimilar competition for their flagship drug Repatha. Additionally, the company's acquisitions and pipeline drugs may not be enough to offset these challenges, leading to a negative outlook for their stock and financial performance in the near future.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares